


 Cite this: *RSC Adv.*, 2024, 14, 39700

# Armored polymyxin B: a nanosystem for combating multidrug-resistant Gram-negative bacilli†

 Jianling Huang,<sup>‡</sup> Xiuwen Hong,<sup>‡</sup> Yunxiang Lv,<sup>a</sup> Yueyue Wang,<sup>a</sup> Kexing Han,<sup>a</sup> Chenghua Zhu<sup>\*c</sup> and Lixu Xie<sup>\*d</sup>

Bacterial infections cause high morbidity and mortality worldwide, and the emergence of drug-resistant bacteria further complicates the treatment of infections. Therefore, it is necessary to continuously develop new treatment methods. Polymyxin B (PMB), as the last line of defense, can combat most aerobic Gram-negative bacilli including common drug-resistant bacteria in clinical practice. However, the suboptimal lung tissue concentration of PMB and dose-dependent nephrotoxicity and neurotoxicity limit its clinical application. The nanodrug delivery system offers several key advantages, including high drug loading capacity, excellent biocompatibility, controlled release mechanisms, and targeted delivery. These features enhance the bioavailability of drugs while simultaneously reducing their toxicity and minimizing side effects. In this study, we designed a targeted nanodrug delivery system (PMB@HMnO<sub>2</sub>@NM) consisting of hollow mesoporous manganese dioxide (HMnO<sub>2</sub>) coated with neutrophil membrane (NM). In a mouse model of acute pneumonia induced by multidrug-resistant *Pseudomonas aeruginosa*, treatment with PMB@HMnO<sub>2</sub>@NM demonstrated the ability to target bacterial aggregation and specifically deliver the drug to the infected lung tissue. This targeted approach resulted in improved survival rates and reduced inflammatory damage without causing adverse effects. The findings of this study suggest the potential for developing a new class of multifunctional nanodrugs, providing new therapeutic strategies for multidrug-resistant (MDR) bacterial infections. Furthermore, these results provide a solid foundation for the design of biomimetic nanosized antibacterial drugs.

 Received 23rd October 2024  
 Accepted 28th November 2024

DOI: 10.1039/d4ra07577c

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## 1. Introduction

Bacterial infections represent a major global health threat, leading to high incidence rates and mortality.<sup>1</sup> Since the discovery of antibiotics, they have become the main means of bacterial infection treatment. However, the prolonged and widespread use of antibiotics has led to the development of bacterial resistance, especially the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria, posing significant challenges to effective clinical treatment.<sup>2</sup>

The development of new antibiotics is a lengthy and costly process, and the rate at which new drug-resistant strains emerge often surpasses the development of new antibiotics. Therefore, it is imperative to explore novel strategies and optimize existing drugs to delay the onset of drug resistance, thereby broadening the available arsenal of treatments for clinicians.

Polymyxins, a class of non-ribosomal polypeptide antimicrobials, exist in five structural forms, with polymyxin B (PMB) and colistin being the only ones currently used in clinical practice.<sup>3</sup> The antimicrobial mechanism of polymyxins involves the binding of their polycationic rings to the phosphate groups on the cell membranes of Gram-negative bacteria, increasing membrane permeability and ultimately leading to bacterial swelling, lysis, and cell death.<sup>4–6</sup> Despite their high sensitivity against common Gram-negative bacilli, polymyxins suffer from low lung tissue concentrations and dose-dependent nephrotoxicity and neurotoxicity,<sup>7</sup> necessitating the exploration of effective strategies to increase the concentration of the drug in lung tissue or to mitigate the associated adverse effects.

In recent years, nanoparticle-based drugs have garnered extensive attention, which can overcome the limitations of traditional antimicrobials, including antibiotic resistance.<sup>8,9</sup> Nanoparticles have been designed both as self-therapeutic

<sup>a</sup>Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, Molecular Diagnosis Center, Bengbu, Anhui, 233000, China. E-mail: [huang021706@163.com](mailto:huang021706@163.com)

<sup>b</sup>Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China. E-mail: [hwx982333@163.com](mailto:hwx982333@163.com)

<sup>c</sup>Nanjing Pukou Hospital of TCM, Pukou Hospital of Chinese Medicine Affiliated to China Pharmaceutical University, Nanjing 210000, China. E-mail: [zhuchenghuacheng@163.com](mailto:zhuchenghuacheng@163.com)

<sup>d</sup>Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road 107#, Jinan 250012, China. E-mail: [lixu\\_xie@163.com](mailto:lixu_xie@163.com)

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra07577c>

‡ Jianling Huang and Xiuwen Hong are co-first authors.



agents and as delivery platforms for antimicrobial cargo to eliminate bacterial infections.<sup>9</sup> Numerous studies have shown that nano-drug delivery systems offer several advantages, such as high drug loading capacity, controlled release, and targeted delivery, significantly improving the bioavailability of antibacterial agents.<sup>10–12</sup> Among them, nanostructured manganese dioxide (MnO<sub>2</sub>) has garnered widespread interest due to its distinctive physical and chemical properties, which encompass pH-responsive degradability in acidic environments, elevated levels of glutathione and H<sub>2</sub>O<sub>2</sub>, superior catalytic properties, as well as favourable biocompatibility.<sup>13–16</sup> However, the lack of active targeting capability in MnO<sub>2</sub> nanoparticles and their vulnerability to immune system clearance significantly hinders efficient drug delivery. To address this issue, researchers have tried to decorate nanoparticles in a biomimetic manner, enabling them to camouflage and evade detection by the immune system.<sup>17,18</sup> Among various biomimetic modification methods, cell membrane-coated nanoparticles have surfaced as a versatile therapeutic platform suitable for a wide range of applications. They are designed to minimize immune system clearance while imparting unique functionalities.<sup>19,20</sup> Neutrophils, which are the most numerous leucocytes in the body, engage in diverse inflammatory responses and serve as the initial line of immune defense against invading pathogens or damaged tissues.<sup>21,22</sup> The neutrophil-derived membrane coating facilitates targeted delivery of encapsulated drugs to the inflamed, infected tissues while neutralizing lipopolysaccharides (LPS) released by bacteria, thereby effectively mitigating the exacerbation of inflammatory responses caused by these toxins.<sup>23,24</sup>

Herein, we present neutrophil membrane-coated hollow MnO<sub>2</sub> (HMnO<sub>2</sub>@NM) nanoparticles for loading PMB and further explore their role in treating pneumonia caused by MDR *Pseudomonas aeruginosa* (PA). This study offered a new idea for the treatment of MDR bacterial infections and lays the foundation for the design of biomimetic antimicrobial nanomedicines.

## 2. Materials and methods

### 2.1. Materials and reagents

Tetraethyl orthosilicate (TEOS) was sourced from Aladdin Reagent Co., Ltd in Shanghai, China. Potassium permanganate (KMnO<sub>4</sub>), methanol, and sodium carbonate (Na<sub>2</sub>CO<sub>3</sub>) were acquired from Sinopharm Chemical Reagent Co., Ltd. The SYTO-9/PI Live and Dead Bacteria Stain Kit was obtained from Zeye Co., Ltd, also located in Shanghai. DiO fluorescent dye, a Peripheral Blood Neutrophil Separation Kit, an MTT cell viability kit, and a BCA protein assay kit were all purchased from Beyotime Biotechnology in Shanghai. LB medium and agar were supplied by BD Difco in the USA. ELISA kits for IL-6 and TNF- $\alpha$  were provided by AiFang Biological Co., Ltd in Wuhan, China.

### 2.2. Preparation of solid silica nanospheres (sSiO<sub>2</sub>)

Solid silica NPs (sSiO<sub>2</sub>) were prepared using the previous method with some modifications.<sup>25</sup> A mixture of 25 mL of absolute ethanol, 0.5 mL of distilled water, and 1.5 mL of

aqueous ammonia was agitated at 500 rpm for 10 min. Subsequently, 0.75 mL of TEOS was gradually introduced and the mixture was stirred at a reduced speed of 150 rpm at 40 °C for 12 h. Following this, sSiO<sub>2</sub> was isolated through centrifugation at 10 000 rpm for 20 min and then rinsed three times with both ethanol and distilled water.

### 2.3. Synthesis of HMnO<sub>2</sub> and PMB@HMnO<sub>2</sub>

Potassium permanganate solution (KMnO<sub>4</sub>) (150 mg) was added to sSiO<sub>2</sub> (20 mg) and the resulting sSiO<sub>2</sub> nanoparticles were utilized as hard templates to synthesize sSiO<sub>2</sub>@MnO<sub>2</sub> nanoparticles with core/shell structures. Finally, the sSiO<sub>2</sub> core of sSiO<sub>2</sub>@MnO<sub>2</sub> was etched away using Na<sub>2</sub>CO<sub>3</sub> solution (2 mol L<sup>-1</sup>) at 60 °C for 12 h, resulting in the production of hollow MnO<sub>2</sub> (HMnO<sub>2</sub>) nanoparticles. For loading PMB, the HMnO<sub>2</sub> solution (0.2 mg mL<sup>-1</sup>) was incubated with various concentrations (0.1, 0.2, 0.4, 0.6 mg mL<sup>-1</sup>) of PMB and stirred for 24 h at 4 °C to form PMB@HMnO<sub>2</sub> nanoparticles.

### 2.4. Synthesis of PMB@HMnO<sub>2</sub>@NM

150 mL of blood samples were collected from 20 healthy adults using anticoagulant tubes. This experiment was approved by the Second Affiliated Hospital of Nanjing Medical University (Approval No: 2023-KY-165-01), and informed consent was obtained from all participants. Neutrophil membranes (NMs) were prepared using the reported method with some modifications.<sup>24,26</sup> At first, neutrophil cells were isolated using specific kits and then lysed in a buffer containing Tris-HCl, mannitol, sucrose, ethylenediaminetetraacetic acid and protease and phosphatase inhibitors. Homogenization was performed in an ice bath using a Dounce homogenizer. The homogenized suspension was centrifuged at 10 000 g for 10 min at 4 °C to remove organelles. The supernatant was then centrifuged at 20 000 g for 60 minutes at 4 °C to collect cell membranes. Cell membranes were resuspended in PBS and neutrophil cell membrane vesicles (NMV) were obtained by extruding 40 times through a 400 nm porous polycarbonate membrane using an Avanti mini-extruder. Membrane content was determined by quantifying membrane surface proteins using a BCA kit (membrane volume = 2 × membrane protein volume). To prepare PMB@HMnO<sub>2</sub>@NM, 0.5 mg per mL PMB@HMnO<sub>2</sub> was mixed with neutrophil cell membrane (1 mg mL<sup>-1</sup>) and coextruded for 40 passes using the Avanti-mini extruder to acquire neutrophil cell membrane-coated nanoparticles.

### 2.5. Characterization of HMnO<sub>2</sub>@NM nanoparticles

Dynamic Light Scattering (Malvern Instruments, UK) was used to assess the size distribution and zeta potentials of the nanoparticles. The elemental composition and morphology of HMnO<sub>2</sub> were determined utilizing transmission electron microscopy (TEM, FEI Tecnai F20) and scanning electron microscopy (SEM, Zeiss Sigma 300). Brunauer-Emmett-Teller (BET) analysis determined the surface area and pore size of HMnO<sub>2</sub> in the HMnO<sub>2</sub>@NM composite. UV-vis spectra were obtained using a PerkinElmer Lambda 750 spectrophotometer.

SDS-PAGE was used to identify the protein content in the membrane component of the nanoparticles.

### 2.6. *In vitro* encapsulation and loading of PMB

1 mmol of PMB and 5 mmol of Fluorescein Isothiocyanate (FITC) were mixed and stirred overnight at 4 °C and purified using dialysis to obtain FITC-labeled PMB. The PMB content in PMB@HMnO<sub>2</sub>@NM nanoparticles was measured using a UV-vis spectrometer at 490 nm. The drug loading and encapsulation efficiencies were calculated as follows:

$$\text{loading efficiency (\%)} = \frac{\text{(the total weight of drug)} - \text{the weight of free drug}}{\text{total weight of nanoparticles}} \times 100$$

### 2.7. Minimum inhibitory concentration (MIC) evaluation

MDR *Pseudomonas aeruginosa* (PA) was kindly provided by the Department of Laboratory Medicine, the First Affiliated Hospital of Bengbu Medical University, for our experiments. The drug sensitivity of bacterial strains is shown in Table S1.† Samples (HMnO<sub>2</sub>@NM, free PMB, PMB@HMnO<sub>2</sub> and PMB@HMnO<sub>2</sub>@NM) were 2-fold diluted from their initial concentration (2048 µg mL<sup>-1</sup>). 100 µL of the bacterial culture (1 × 10<sup>7</sup> CFU mL<sup>-1</sup>) was added to a 96-well plate and incubated (37 °C) with 100 µL of each sample. The MIC value was determined by evaluating the visible growth of microorganisms.

### 2.8. *In vitro* macrophage phagocytosis

RAW 264.7 (1 × 10<sup>6</sup>) was inoculated into 12-well plates and incubated at 37 °C for 12 h. Then, 100 µL HMnO<sub>2</sub>@NM (10 µg per mL HMnO<sub>2</sub>), free PMB, PMB@HMnO<sub>2</sub> (10 µg mL<sup>-1</sup>) and PMB@HMnO<sub>2</sub>@NM were added to each well. After 4 h of incubation, the cells were washed, fixed with 4% paraformaldehyde at room temperature, stained with DAPI, and then observed under a confocal microscope to assess macrophage phagocytosis.

### 2.9. Determination of intracellular bacterial content

SYTO-9-labeled PA and Hoechst 33 342-stained RAW 264.7 cells were cultured in antibiotic-free DMEM medium at an MOI of 10 : 1 and incubated at 37 °C for 2 h. The cells were washed three times with saline to remove non-phagocytosed bacteria. Fresh DMEM medium containing HMnO<sub>2</sub>@NM, free PMB, PMB@HMnO<sub>2</sub> and PMB@HMnO<sub>2</sub>@NM (10 µg per mL HMnO<sub>2</sub>) were added to the RAW 264.7 cells and co-incubated for 2 h. Then, the cells were observed and photographed using a laser confocal microscope. In order to further quantify the effect of bacterial removal, 1% Trillatone X-100 was used to destroy RAW 264.7 cells, and 100 µL of appropriately diluted bacterial suspension was applied to LB plates, and the bacteria in different treatment groups were counted.

### 2.10. Crystalline violet assay

100 µL PMB@HMnO<sub>2</sub>, PMB@HMnO<sub>2</sub>@NM nanoparticles (100 µg mL<sup>-1</sup>) and free PMB (47.08 µg mL<sup>-1</sup>) were added to the

bacterial suspension (100 µL, 1 × 10<sup>7</sup> CFU mL<sup>-1</sup>). The control group received 100 µL of PBS. After incubation for 24 h, the wells were collected and washed three times and then 0.1% (v/v) crystal violet solution was added. One hour later, 200 µL of 95% (v/v) ethanol was utilized to dissolve the crystal violet. The experiment was conducted in triplicate, and the absorbance was determined at 595 nm using a microplate reader. Bacterial biofilm inhibition was calculated according to the following formula:

$$\text{Inhibition of bacterial biofilm formation (\%)} = [1 - (\text{absorbance of drug-treated cells/absorbance of control cells in the control group})] \times 100.$$

### 2.11. Cell cytotoxicity assay

BEAS-2B cells were plated in 96-well (1 × 10<sup>5</sup> cells per well) and incubated for 12 h. After throwing away the medium, the cells were washed with PBS. Different concentrations (3.125, 6.25, 12.5, 25, 50, 100, and 200 µg mL<sup>-1</sup>) of PMB@HMnO<sub>2</sub>@NM in a complete medium were then added into the wells, and further incubated for 24 h. MTT assay was used to evaluate cell viability.

### 2.12. Animal studies

Female BALB/c mice (18–20 g) were purchased from Yangzhou University Laboratory Animal Center and raised under specific pathogen-free (SPF) conditions and provided with enough food and water. All animal experiments were performed in accordance with the Guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals and approved by the Ethics Committee of Animal Care and Welfare, Nanjing Medical University (Approval Number: 2404092). Mice were allocated and randomly divided into five groups: control, HMnO<sub>2</sub>@NM, free PMB, PMB@HMnO<sub>2</sub> and PMB@HMnO<sub>2</sub>@NM groups (*n* = 6 per group). After the mice were anesthetized, each mouse was inoculated *via* endotracheal inoculation with 100 µL of PBS containing 4 × 10<sup>7</sup> CFU of clinical MDR PA to induce acute pneumonitis. 2 h later, mice were injected *i.v.* with 100 µL of saline, HMnO<sub>2</sub>@NM, free PMB, PMB@HMnO<sub>2</sub>, and PMB@HMnO<sub>2</sub>@NM (2 mg per kg PMB). The procedure was repeated on the third day, followed by euthanasia of the mice on the fifth day. Blood and lung tissue samples were collected to quantify IL-6 and TNF-α levels *via* ELISA and assess bacterial burden.

### 2.13. Statistical analysis

Statistical analyses were performed using GraphPad Prism 8.0 software. Results were reported as mean ± SD. Significance was evaluated through Student's *t*-test or one-way ANOVA, where ns denoted non-significance, \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001.

## 3. Results and discussion

### 3.1. Preparation and characterization of HMnO<sub>2</sub>@NM nanoparticles (NPs)

HMnO<sub>2</sub> nanoparticles were synthesized by a three-step reaction process (Fig. 1a). In brief, solid SiO<sub>2</sub> nanoparticles (Fig. S1a†) were synthesized using the Stöber method.<sup>25</sup> A uniform coating of mesoporous MnO<sub>2</sub> was subsequently deposited on the SiO<sub>2</sub>




Fig. 1 Synthesis and characterization of  $\text{HMnO}_2@NM$  nanoparticles. (a) Scheme of synthetic procedure of  $\text{HMnO}_2@NM$ . (b) SEM images of  $\text{HMnO}_2$  scale bar: 100 nm. (c) TEM images of  $\text{HMnO}_2$ , (d)  $\text{HMnO}_2@NM$  and (e) neutrophil membrane vesicles. (f) Hydrodynamic sizes of  $\text{HMnO}_2$  and  $\text{HMnO}_2@NM$  measured by DLS ( $n = 3$ ). (g) Zeta potentials of  $\text{HMnO}_2$  and  $\text{HMnO}_2@NM$  were detected by DLS. (h) Protein profiles of the neutrophil membrane vesicles and  $\text{HMnO}_2@NM$  nanoparticles as analyzed using SDS-PAGE. (i) *In vitro* stability of  $\text{HMnO}_2@NM$  nanoparticles maintained in  $\text{H}_2\text{O}$ , PBS, and DMEM cell culture medium at  $4^\circ\text{C}$  for 2 weeks ( $n = 3$ ). (j)  $\text{N}_2$  adsorption/desorption isotherms. (k) Pore-size distribution curve of  $\text{HMnO}_2$  nanoparticles. (l) *In vitro* profiles of cumulative release for PMB released from  $\text{PMB@HMnO}_2$  and  $\text{PMB@HMnO}_2@NM$  nanoparticles in PBS at pH 7.4 and 5.5. Data are presented as the mean  $\pm$  SD ( $n = 3$ ). \* $p < 0.05$ , \*\* $p < 0.01$ .

nanoparticle surface through the addition of  $\text{KMnO}_4$  to form  $\text{SiO}_2@MnO_2$  nanoparticles (Fig. S1b<sup>†</sup>). In the end,  $\text{SiO}_2$  was etched away to obtain  $\text{HMnO}_2$  particles. The scanning electron microscope (SEM) and transmission electron microscopy (TEM) images of  $\text{HMnO}_2$  showed a uniform spherical hollow structure with an average particle diameter of 100 nm (Fig. 1b and c). After coating with neutrophil membrane (NM), a lipid layer structure could be seen on the surface of  $\text{HMnO}_2$  (Fig. 1d and e). As measured by dynamic light scattering (DLS), the hydrodynamic size of the membrane-cloaked nanoparticles increased from  $114.75 \pm 8.8$  nm to  $133.8 \pm 5.44$  nm after coating with the NM layer (Fig. 1f). The zeta potential changed from  $-22.64 \pm 0.05$  mV to  $-7.93 \pm 0.32$  mV (Fig. 1g). The SDS-PAGE analysis confirmed that the membrane proteins originating from NM were well retained on the surface of  $\text{HMnO}_2@NM$  nanoparticles after coating (Fig. 1h). Furthermore,  $\text{HMnO}_2@NM$  exhibited excellent colloidal stability and dispersion after 2 weeks of incubation in water, pH 7.4 phosphate buffer solution (PBS) and DMEM medium (Fig. 1i).

### 3.2. pH-Dependent drug behaviours

Brunauer–Emmett–Teller (BET) results showed that  $\text{HMnO}_2$  had large specific surface area of  $370.82 \text{ m}^2 \text{ g}^{-1}$  (Fig. 1j) and


average pore size of 10.91 nm (Fig. 1k), which was beneficial for drug loading and delivery. To prepare PMB-loaded nanoshells, FITC labeled PMB was used to establish a standard curve, plotting various concentrations of lysostaphin protein against their corresponding optical absorption intensities. UV-vis spectra of FITC-labeled PMB exhibited an absorption peak for FITC at 490 nm, indicating successful labeling of PMB (Figs. S2a–c<sup>†</sup>). We mixed  $\text{HMnO}_2$  nanoparticles with different concentrations of PMB under overnight stirring and sequentially coated with the cell membrane. At the PMB :  $\text{HMnO}_2$  ratio of 3 : 1, the PMB loading efficiency of  $\text{HMnO}_2@NM$  reached 47.08% (Fig. S3<sup>†</sup>). The responsiveness of  $\text{HMnO}_2@NM$  to the microenvironment within biofilms is a pivotal characteristic, enabling targeted drug release directly at the site of infection.  $\text{PMB@HMnO}_2$  and  $\text{PMB@HMnO}_2@NM$  exhibited quite different drug release behaviours under varied pH (Fig. 1l). In a neutral solution (pH 7.4), approximately 35.2% of PMB was released from  $\text{PMB@HMnO}_2$  after 48 h. However, only 15.9% of PMB was released from  $\text{PMB@HMnO}_2@NM$ , suggesting that the presence of cell membranes can partially shield the encapsulated drugs from leakage. Whilst in an acidic solution (pH 5.5), the decomposition of  $\text{HMnO}_2$  could induce about 77.8% and 69.2% PMB release of  $\text{PMB@HMnO}_2$  and  $\text{PMB@HMnO}_2@NM$  within 48 h, respectively.

### 3.3. *In vitro* antibacterial effect of $\text{PMB@HMnO}_2@NM$

In order to clarify the specific recognition function of  $\text{HMnO}_2@NM$  for bacteria with the assistance of neutrophil membrane,  $\text{HMnO}_2$  and  $\text{HMnO}_2@NM$  nanoparticles were co-incubated with PA for 4 h and observed by SEM. Fig. 2a shows that a large number of nanoparticles were attached to the surface after the exposure to  $\text{HMnO}_2@NM$ , while few nanoparticles were found on the surface of PA when exposed to  $\text{HMnO}_2$  nanoparticles. This indicated that NM promoted the binding of  $\text{HMnO}_2@NM$  to PA and had a targeting effect for bacteria.

To evaluate the influence of encapsulating PMB within  $\text{HMnO}_2$  on its enzymatic activity, we determined the minimal inhibitory concentration (MIC) for  $\text{HMnO}_2@NM$ ,  $\text{PMB@HMnO}_2@NM$  and free PMB. Notably,  $\text{PMB@HMnO}_2@NM$  demonstrated an MIC value of  $4 \mu\text{g mL}^{-1}$ , which was equivalent to that of free PMB. Conversely,  $\text{HMnO}_2@NM$  alone exhibited no bactericidal activity (Table 1).

These findings indicate that encapsulation within nanoparticles does not compromise the antibacterial efficacy of the loaded PMB. As shown in Fig. 2b,  $\text{PMB@HMnO}_2@NM$  eliminated the bacteria at a faster rate than free PMB or  $\text{HMnO}_2@NM$  alone. After 4 h of incubation,  $\text{PMB@HMnO}_2@NM$  completely eliminated all bacteria, whereas samples treated with PMB alone still contained live bacteria in the same time range. These results of the live/dead staining further revealed that bacterial cells treated with PBS and  $\text{HMnO}_2@NM$  displayed mostly green fluorescence (indicating live bacteria). In contrast, cells exposed to PMB and  $\text{PMB@HMnO}_2@NM$  exhibited intense red fluorescence,




**Fig. 2** Bactericidal activity *in vitro*. (a) SEM images of PA after treatment with PBS, HMnO<sub>2</sub> and HMnO<sub>2</sub>@NM nanoparticles. (b) Bacteria-killing kinetics of PBS (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. (c) Illustrative fluorescence images for live/dead bacterial staining assay of MDR PA after treatment with PBS (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. Scale bar: 20 μm. (d) Representative SEM images of MDR PA at 4 h after treatment with PBS (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM (47.08 μg mL<sup>-1</sup> of PMB).

**Table 1** Assessment of the minimum inhibitory concentration (MIC) of HMnO<sub>2</sub>@NM, PMB@HMnO<sub>2</sub>, PMB@HMnO<sub>2</sub>@NM nanoparticles and free PMB

Bacterial strains	MIC (μg mL <sup>-1</sup> )			
	HMnO <sub>2</sub> @NM	PMB@HMnO <sub>2</sub>	PMB@HMnO <sub>2</sub> @NM	PMB
MDR-PA	No inhibition	4	4	4

signifying the disruption of their cell membranes and subsequent permeability to PI (Fig. 2c). Bacteria treated with PBS or HMnO<sub>2</sub>@NM exhibited intact cell walls, smooth cell membranes, and a dense, uniform cytoplasm. Conversely, bacteria exposed to PMB or PMB@HMnO<sub>2</sub>@NM displayed disrupted or damaged cell walls, along with wrinkled and deformed cell membranes. These findings indicated that PMB encapsulated within PMB@HMnO<sub>2</sub>@NM was equally efficacious as free PMB in eliminating PA by disrupting its cell wall structure and ultimately causing bacterial lysis (Fig. 2d).

To investigate the bactericidal effect of PMB@HMnO<sub>2</sub>@NM on MDR PA within macrophages, we labeled PA and RAW 264.7 cells with SYTO-9 and Hoechst 33342, respectively, and subsequently observed them using Confocal Laser Scanning




**Fig. 3** (a) Confocal fluorescence images of PA-infected RAW264.7 cells treated with PBS (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. Scale bar, 20 μm. (b) Photographs of CFU and CFU counting (c) of PA released from macrophages under different treatments. (d) Crystal violet staining photographs of biofilms after different treatments. (e) Inhibition rates of biofilms after treatment with PBS (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM (47.08 μg mL<sup>-1</sup> of PMB) ( $n = 3$ , \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , n.s. means no significance. Data are expressed in mean ± SD).

Microscopy (CLSM). Macrophages treated with PMB@HMnO<sub>2</sub>@NM exhibited superior PA clearance capability compared to other groups, evidenced by a decrease in green fluorescence spots within the macrophages (Fig. 3a). To quantify this effect further, we lysed the cells using detergent and enumerated the bacterial colony-forming units (CFU). The reduction in CFU numbers in the PA-infected macrophage cells following PMB@HMnO<sub>2</sub>@NM treatment confirmed the enhanced bacterial clearance ability (Fig. 3b and c).

Infections caused by PA often manifest as biofilms, which feature an extracellular polymer matrix that significantly impedes antibiotic penetration, leading to a notable increase in bacterial resistance, ranging from 100 to 1000 fold.<sup>27</sup> Thus, we further evaluated the *in vitro* biofilm eradication activities of PMB@HMnO<sub>2</sub>@NM. Through crystal violet staining, we observed that biofilms treated with PBS and HMnO<sub>2</sub>@NM remained largely viable and structurally intact, indicative of negligible antibiofilm activity. Conversely, the PMB@HMnO<sub>2</sub>@NM group showed substantial biomass loss (Fig. 3d and e), highlighting its potent anti-biofilm potential.

#### 3.4. Biodistribution of HMnO<sub>2</sub>@NM *in vivo*

To verify the lung targeting ability of HMnO<sub>2</sub>@NM, we constructed ICG@HMnO<sub>2</sub> and ICG@HMnO<sub>2</sub>@NM nanoparticles loaded with the fluorescent dye ICG and injected them *via* the tail vein into mice with pneumonia caused by MDR PA.



**Fig. 4** Bactericidal activity *in vivo*. (a) *In vivo* fluorescence images of MDR PA lung-infected mice at various time points post-intravenous injection of ICG@HMnO<sub>2</sub> and ICG@HMnO<sub>2</sub>@NM. (b) Lung bacterial loads in mice post-treatment with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. (c) Giemsa staining results of lung tissue after treatment with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. Scale bars: 20 μm. (d) H & E staining of lung tissue after treatment with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. Scale bars: 20 μm. (e) Serum levels of IL-6 and TNF-α collected after treated with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. (f) Percentage survival of pneumonia mice treated with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM (*n* = 6, \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, n.s. means no significance. Data are expressed in mean ± SD).

Representative time-dependent *in vivo* imaging was then performed using the Xenogen IVIS system. As shown in Fig. 4a, the ICG@HMnO<sub>2</sub>@NM group displayed a higher level of fluorescence intensity in the lungs compared to the ICG@HMnO<sub>2</sub> group, indicating that ICG@HMnO<sub>2</sub>@NM could accumulate in the lungs. This accumulating ability was essential for targeting the delivery of drugs to the lungs.

### 3.5. PMB@HMnO<sub>2</sub>@NM reduces bacterial load in lung tissue and alleviates the inflammatory response

Given the potent bactericidal activity demonstrated *in vitro*, along with the lung targeting capability of PMB@HMnO<sub>2</sub>@NM, we assessed its therapeutic efficacy in mice with acute pneumonia caused by MDR PA. The mice were inoculated intratracheally (i.t.) with MDR PA ( $4 \times 10^7$  CFU) to induce acute pneumonia. After 2 h of post-inoculation, the mice were intravenously administered either saline (control), HMnO<sub>2</sub>@NM, PMB, or PMB@HMnO<sub>2</sub>@NM. Notably, the CFU counts in mice treated with PMB@HMnO<sub>2</sub>@NM were significantly lower than those in other groups at 48 h of post-intravenous injection,

indicating superior *in vivo* bactericidal activity (Fig. 4b). This enhanced therapeutic effect may be attributed to the higher concentration of PMB achieved in the alveoli of mice treated with PMB@HMnO<sub>2</sub>@NM compared to those receiving free PMB. Meanwhile, the results of Giemsa staining showed the lowest bacterial residues in the lung tissue after treatment of PMB@HMnO<sub>2</sub>@NM (Fig. 4c). We further assessed lung inflammation in mice subjected to various treatments to demonstrate the therapeutic benefits of PMB@HMnO<sub>2</sub>@NM in acute pneumonia caused by MDR PA. Histological analysis of lung tissues in the control group showed severe alveolar damage and widespread infiltration of inflammatory cells, indicative of extensive lung pathology (Fig. 4d). Mice treated with free PMB exhibited a decrease in alveolar count, incomplete alveolar expansion, and alveolar fusion. Compared to the control, the PMB@HMnO<sub>2</sub>@NM treatment markedly alleviated lung injury, exhibiting a notable decrease in inflammatory cell infiltration, hemorrhage, and alveolar damage. Next, we assessed cytokine production in mouse serum using ELISA assays. As illustrated in Fig. 4e, mice treated with PMB@HMnO<sub>2</sub>@NM exhibited the lowest production of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). To evaluate the impact of PMB@HMnO<sub>2</sub>@NM on survival rates in mice with pneumonia, we established a severe pneumonia model by inoculating high doses of PA ( $4 \times 10^8$  CFU per mouse). The outcomes demonstrated that all mice in the control and HMnO<sub>2</sub>@NM group died within 3 days, while the survival rate in the PMB@HMnO<sub>2</sub>@NM group was beyond 70% within 7 days (Fig. 4f). Collectively, these results demonstrate that PMB@HMnO<sub>2</sub>@NM treatment effectively reduces the bacterial burden in lung tissues, alleviating the inflammatory response, decreasing cytokine levels, and significantly improving the survival rates of mice with pneumonia.

### 3.6. Biosafety of PMB@HMnO<sub>2</sub>@NM *in vitro* and *in vivo*

Normal human bronchial epithelial cells (BEAS-2B) were utilized to assess the cytotoxicity of PMB@HMnO<sub>2</sub>@NM nanoparticles *in vitro* using MTT assay. PMB@HMnO<sub>2</sub>@NM displayed favourable biocompatibility, as evidenced by cell viabilities exceeding 80% following 24 h of incubation at various concentrations (Fig. 5a). To investigate the long-term safety profile, healthy mice were subjected to treatments with these compounds. Over a 28 days period, none of the mice died, and there were no significant changes in the body weight among the treated mice, indicating that PMB@HMnO<sub>2</sub>@NM does not exhibit systemic toxicity (Fig. 5b). Hematological parameters, including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), creatinine (Cre), and blood urea nitrogen (BUN) remained within normal ranges on 28th days (Fig. 5c-f). Furthermore, histological examinations of vital organs such as the heart, kidney, liver, spleen, and lungs revealed no discernible damage in mice treated with PMB@HMnO<sub>2</sub>@NM (Fig. 5g). These findings collectively underscore the exceptional biosafety of PMB@HMnO<sub>2</sub>@NM, indicating its absence of both acute and chronic toxicity, both locally and systemically.




Fig. 5 Biosafety of PMB@HMnO<sub>2</sub>@NM nanoparticles. (a) Cytotoxicity in BEAS-2B cells after being treated with various concentrations of PMB@HMnO<sub>2</sub>@NM for 24 h. (b) The body weight change of mice treated with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM during 28 days. (c–f) Analysis of blood biochemical parameters of mice in various treatment groups on day 28 post-administration, encompassing (c) ALT, (d) AST, (e) BUN and (f) creatinine (Cre). (g) H & E staining of vital organ sections of mice at day 28 after treated with saline (control), HMnO<sub>2</sub>@NM, PMB and PMB@HMnO<sub>2</sub>@NM. Scale bar, 100 µm ( $n = 3$ ).

## 4. Conclusions

In summary, we successfully developed a novel biomimetic nanoplatform, PMB@HMnO<sub>2</sub>@NM, which integrates an HMnO<sub>2</sub> nanoparticle core with a neutrophil membrane coating for the targeted systemic treatment of pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa*. This nanoplatform demonstrated efficacy in delivering antibacterial drugs directly to the infectious sites. Treatment with PMB@HMnO<sub>2</sub>@NM significantly enhanced survival rates, reduced bacterial loads, and mitigated inflammatory damage in infected lungs. These promising results underscore the clinical translation potential of PMB@HMnO<sub>2</sub>@NM as a novel therapeutic option for *Pseudomonas aeruginosa*-infected lung diseases, offering a significant advancement in the treatment of MDR bacterial infections.

## Data availability

The authors confirm that the data supporting the study's findings are provided in the article, with some placed in the ESI.†

## Author contributions

J. H. designed and performed experiments and analyzed data; X. H. and Y. L. performed the experiments; Y. W. and K. H. performed experiments and analyzed the data. C. Z. and L. X. wrote the paper and led the project. All authors have read and agreed to the published version of the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This research was supported by the Clinical Medicine Translation Special Program of the Key Research and Development Plan in Anhui Province (202204295107020033).

## References

- 1 D. Averbuch, *Bacterial Infections*, 2019, pp. 265–272.
- 2 A. Rodrigo-Troyano and O. Sibila, *Respirology*, 2017, **22**, 1288–1299.
- 3 J. Molina, E. Cordero and J. Pachon, *Expert Opin. Pharmacother.*, 2009, **10**, 2811–2828.
- 4 F. Rabanal and Y. Cajal, *Nat. Prod. Rep.*, 2017, **34**, 886–908.
- 5 J. Yin, Q. Meng, D. Cheng, J. Fu, Q. Luo, Y. Liu and Z. Yu, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 3771–3780.
- 6 M. Hussein, X. Hu, O. Paulin, S. Crawford, Z. Q. Tony, M. Baker, E. K. Schneider-Futschik, Y. Zhu, J. Li and T. Velkov, *Comput. Struct. Biotechnol. J.*, 2020, **18**, 2247–2258.
- 7 Q. J. Yang, B. X. Xiang, M. H. Song, C. Y. Yang, J. H. Liang, Y. L. Xie and X. C. Zuo, *Pharmacotherapy*, 2024, **44**, 631–641.
- 8 R. Solanki, N. Makwana, R. Kumar, M. Joshi, A. Patel, D. Bhatia and D. K. Sahoo, *RSC Adv.*, 2024, **14**, 33568–33586.
- 9 A. Gupta, S. Mumtaz, C. H. Li, I. Hussain and V. M. Rotello, *Chem. Soc. Rev.*, 2019, **48**, 415–427.
- 10 J. Makabenta, A. Nabawy, C. H. Li, S. Schmidt-Malan, R. Patel and V. M. Rotello, *Nat. Rev. Microbiol.*, 2021, **19**, 23–36.
- 11 C. H. Li, X. Chen, R. F. Landis, Y. Geng, J. M. Makabenta, W. Lemnios, A. Gupta and V. M. Rotello, *ACS Infect. Dis.*, 2019, **5**, 1590–1596.
- 12 N. F. Virzi, V. Greco, S. Stracquadanio, A. Jasim, K. Greish, P. Diaz-Rodriguez, N. P. Rotondo, S. Stefani, V. Pittala and A. Giuffrida, *RSC Adv.*, 2024, **14**, 34066–34080.
- 13 H. Lu, X. Zhang, S. A. Khan, W. Li and L. Wan, *Front. Microbiol.*, 2021, **12**, 761084.
- 14 T. Du, S. Chen, J. Zhang, T. Li, P. Li, J. Liu, X. Du and S. Wang, *Nanomaterials*, 2020, **10**, 1545.
- 15 C. Wang, Y. Xiao, W. Zhu, J. Chu, J. Xu, H. Zhao, F. Shen, R. Peng and Z. Liu, *Small*, 2020, **16**, e2000589.
- 16 C. Qian, G. Zhao, M. Huo, M. Su, X. Hu, Q. Liu and L. Wang, *RSC Adv.*, 2024, **14**, 17612–17626.
- 17 X. Wang, Z. Xia, H. Wang, D. Wang, T. Sun, E. Hossain, X. Pang and Y. Liu, *Theranostics*, 2023, **13**, 3224–3244.

- 18 W. Yi, P. Xiao, X. Liu, Z. Zhao, X. Sun, J. Wang, L. Zhou, G. Wang, H. Cao, D. Wang and Y. Li, *Signal Transduct. Targeted Ther.*, 2022, 7, 386.
- 19 X. Geng, Y. Chen, Z. Chen, X. Wei, Y. Dai and Z. Yuan, *Ultrason. Sonochem.*, 2022, 84, 105972.
- 20 Y. Jia, L. Zhang, J. Xu and L. Xiang, *Biomed. Mater.*, 2024, 19, 4.
- 21 S. Carnevale, I. Di Ceglie, G. Grieco, A. Rigatelli, E. Bonavita and S. Jaillon, *Front. Immunol.*, 2023, 14, 1180810.
- 22 C. Rosales, *J. Leukoc. Biol.*, 2020, 108, 377–396.
- 23 C. Li, Y. Gan, Z. Li, M. Fu, Y. Li, X. Peng, Y. Yang, G. B. Tian, Y. Y. Yang, P. Yuan and X. Ding, *Biomater. Res.*, 2023, 27, 30.
- 24 J. Liu, X. Chen, L. Xu, F. Tu, X. Rui, L. Zhang, Z. Yan, Y. Liu and R. Hu, *Nanomedicine*, 2023, 48, 102640.
- 25 W. Stöber, A. Fink and E. Bohn, *J. Colloid Interface Sci.*, 1968, 26(1), 62–69.
- 26 X. Wu, Z. Lin, C. Zhao, L. Liu, K. Zhang, J. Lai, Q. F. Meng, G. Yao, Q. Huang, X. Z. Zhao and L. Rao, *Biosens. Bioelectron.*, 2022, 213, 114425.
- 27 W. Feng, G. Li, X. Kang, R. Wang, F. Liu, D. Zhao, H. Li, F. Bu, Y. Yu, T. F. Moriarty, Q. Ren and X. Wang, *Adv. Mater.*, 2022, 34, e2109789.